In the phase 2 clinical trial, 3-26% of patients who used retatrutide experienced vomiting, compared to 1% in the placebo group
Pharmacokinetics behind split dosing The pharmacokinetic argument for microdosing is straightforward and mathematically sound
The changes resulted in a decrease in serum GLP-1 along with insulin resistance and metabolic dysfunction
Explore the high-cost environment and what it means for your organization: Lauren Safranek, SHRM-SCP, good read here
Long-Term Tolerability: We need to know if the side effects remain manageable over years of continuous use
The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment